STOXPO
  • Latest News
  • Technology
    • Software
    • Semiconductors
  • Healthcare
    • Biotechnology
    • Pharmaceuticals
  • Crypto
    • Altcoins
    • Bitcoin
    • Ethereum
  • Companies
    • Micro-Cap
    • Small-Cap
    • Mid-Cap
    • Large-Cap
    • Mega-Cap
  • Q&A’s
  • Contributions
No Result
View All Result
  • Latest News
  • Technology
    • Software
    • Semiconductors
  • Healthcare
    • Biotechnology
    • Pharmaceuticals
  • Crypto
    • Altcoins
    • Bitcoin
    • Ethereum
  • Companies
    • Micro-Cap
    • Small-Cap
    • Mid-Cap
    • Large-Cap
    • Mega-Cap
  • Q&A’s
  • Contributions
No Result
View All Result
STOXPO
No Result
View All Result
Home Companies Large-Cap
drugs-4

Eli Lilly Introduces Affordable Version of Zepbound to Address Soaring Demand and Combat Counterfeit Drugs

byLiliana Vida
August 27, 2024
in Large-Cap, Pharmaceuticals
Reading Time: 3 mins read
Share on TwitterShare on LinkedIn

New Single-Dose Vials of Zepbound Priced at Half the Cost Aim to Increase Access for Uninsured Patients

Eli Lilly (LLY) has made a significant move to enhance patient access to its popular weight loss drug, Zepbound, by releasing a new version at nearly half its usual monthly list price. The new single-dose vials are designed to meet the needs of patients who lack insurance coverage, including Medicare beneficiaries, while also addressing the growing demand for the drug amidst the rising threat of cheaper, counterfeit alternatives.

Expanding Access Through Affordable Pricing

On Tuesday, Eli Lilly announced the release of 2.5-milligram and 5-milligram single-dose vials of Zepbound, priced at $399 and $549 per month, respectively. These prices are substantially lower than the typical cost of Zepbound, which, like other popular weight loss drugs such as Novo Nordisk’s Wegovy, is usually around $1,000 per month before insurance rebates. This price reduction is aimed at making Zepbound more accessible to the millions of patients who are currently uninsured for obesity treatments, particularly those enrolled in Medicare or employer-sponsored health plans that do not cover such medications.

Patients can now purchase these single-dose vials directly from Eli Lilly’s website, where they are available through a new “self-pay pharmacy” section. The company has partnered with a third-party digital pharmacy, Gifthealth, to process prescriptions electronically and handle the packaging and delivery of the vials to eligible patients. This direct-to-consumer model allows patients to bypass traditional supply chain markups, offering them a transparent and predictable pricing structure.

Addressing Supply and Safety Concerns

The release of these new vials also serves a dual purpose: increasing the U.S. supply of Zepbound and ensuring that patients have safe access to the drug. As demand for Zepbound continues to surge, Eli Lilly has found that manufacturing these vials is easier and more efficient than producing the currently available autoinjector pens. This increased production capacity is crucial for meeting the growing needs of patients while maintaining the quality and availability of the drug.

The move comes at a time when counterfeit and unregulated versions of weight loss drugs are flooding the market, posing significant risks to patients. Eli Lilly and its rival, Novo Nordisk, have been actively fighting against these illicit versions by suing wellness clinics, medical spas, and compounding pharmacies across the U.S. over the past year. The proliferation of these knock-offs has been fueled by the high demand for weight loss medications, particularly those containing the active ingredient tirzepatide, which is used in both Zepbound and Eli Lilly’s diabetes drug, Mounjaro.

To combat this, Eli Lilly has emphasized the importance of ensuring that patients and healthcare providers are receiving genuine, FDA-approved Zepbound. The company has stated that distributing the vials through its direct-to-consumer site will help protect the public from the dangers posed by counterfeit or unsafe versions of its medications.

Implications for Patients and the Market

The introduction of these more affordable vials is expected to benefit a wide range of patients, particularly those who are willing to pay out-of-pocket for Zepbound due to lack of insurance coverage. Patrik Jonsson, president of Eli Lilly diabetes and obesity, noted that Medicare beneficiaries are not eligible for the company’s savings card programs, which allow patients with insurance to pay as little as $25 out-of-pocket or $550 for those without coverage. Therefore, the new vial pricing provides a viable alternative for those who might otherwise turn to unregulated or compounded medications.

The move also reinforces Eli Lilly’s commitment to patient safety and the integrity of its products. By ensuring that Zepbound is both accessible and affordable, the company aims to reduce the reliance on untested, unapproved, and potentially dangerous alternatives that have been gaining traction in the market.

As the landscape of weight loss treatments continues to evolve, Eli Lilly’s strategic decision to lower the cost of Zepbound and increase its availability could set a new standard in the industry, ultimately benefiting patients by providing them with safe, effective, and affordable options for managing obesity.

You might like this article:Ulta Beauty’s Q2 Earnings Preview: A Focus on Market Share Recovery Amid Competitive Pressures

Tags: BreakingGrowthMoversNews
Previous Post

Ulta Beauty’s Q2 Earnings Preview: A Focus on Market Share Recovery Amid Competitive Pressures

Next Post

JD.com Launches $5 Billion Share Buyback Amidst Sluggish Chinese Retail Market

Related Posts

Anthropic Leveraged ETFs: What GraniteShares’ AIL and ANS Offer Traders

byLiliana Vida
November 20, 2026
0

GraniteShares’ 2x long AIL and 2x short ANS ETFs give traders daily leveraged exposure to Anthropic stock. Launch date, how...

semiconductor-6

Qualcomm CEO Rejects AI Market Correction Fears as Company Expands Into Data Centers

byLuca Blaumann
November 12, 2026
0

Cristiano Amon highlights strong semiconductor demand, supply shortages, and Qualcomm’s growing AI infrastructure ambitions despite widespread technology stock volatility. Qualcomm...

CoreWeave Q3 Revenue Surges Nearly 170% to $3.66 Billion as AI Demand Accelerates

byLuca Blaumann
November 11, 2026
0

AI cloud infrastructure provider beats Wall Street expectations, raises full-year revenue guidance, and reports a $132.5 billion backlog amid continued...

Next Post
investing

JD.com Launches $5 Billion Share Buyback Amidst Sluggish Chinese Retail Market

Latest News

Anthropic Leveraged ETFs: What GraniteShares’ AIL and ANS Offer Traders

KULR Technology Secures $14.8 Million Purchase Order for Advanced Energy Storage Systems

SELLAS Life Sciences Stock Soars 170% Following Positive Phase 3 Leukemia Vaccine Results

Qualcomm CEO Rejects AI Market Correction Fears as Company Expands Into Data Centers

D-Wave Quantum Q3 Revenue Climbs 21% as Backlog Surges Over 1,200%

Based on Your Interest

Artificial Intelligence

CoreWeave Q3 Revenue Surges Nearly 170% to $3.66 Billion as AI Demand Accelerates

November 11, 2026
Artificial Intelligence

CoreWeave Earnings Preview: Why Guidance Matters More Than Q3 Results

November 10, 2026
investing
Artificial Intelligence

D-Wave Quantum Q3 Revenue Rises 21% as Bookings Surge and Quantum Adoption Expands

November 10, 2026

Recommended

Auto Manufacturers

Lucid Secures $1.75 Billion Liquidity Boost From Saudi PIF to Support Turnaround

November 10, 2026
Artificial Intelligence

KULR Technology Revenue Surges 197% in Q3 as Battery Sales Nearly Quadruple

November 10, 2026
Aerospace & Defense

Rocket Lab Q3 Revenue Surges 73% to $268 Million, Beating Wall Street Expectations

November 9, 2026
Artificial Intelligence

IonQ Shares Climb as Company Expands Government Reach Through Carahsoft Partnership

November 9, 2026
Aerospace & Defense

AST SpaceMobile and Rakuten Launch Joint Venture Backed by $1 Billion in Japanese Government Funding

November 9, 2026
Stoxpo

Follow us on social media:

Highlights

  • Anthropic Leveraged ETFs: What GraniteShares’ AIL and ANS Offer Traders
  • KULR Technology Secures $14.8 Million Purchase Order for Advanced Energy Storage Systems
  • SELLAS Life Sciences Stock Soars 170% Following Positive Phase 3 Leukemia Vaccine Results
  • Qualcomm CEO Rejects AI Market Correction Fears as Company Expands Into Data Centers
  • D-Wave Quantum Q3 Revenue Climbs 21% as Backlog Surges Over 1,200%

Category

  • Blog
  • Communication Services
    • Entertainment
    • Internet
    • Telecommunications
  • Companies
    • Large-Cap
    • Mega-Cap
    • Micro-Cap
    • Mid-Cap
    • Small-Cap
  • Consumer Cyclical
    • Auto Manufacturers
    • Casinos & Gambling
    • Ground Transportation
    • Hospitality
      • Casinp
      • Resorts & Lodging
      • Restaurants
      • Travel
        • Airlines
    • Retail
    • Textiles, Apparel & Luxury Goods
  • Consumer Defensive
    • Beverages
    • Discount Stores
    • Distributor
    • Ecommerece
    • Electrical Equipment
    • Foods
    • Household & Personal Products
    • Leisure Products
    • Tobacco
  • Contributions
  • Crypto
    • Altcoins
    • Bitcoin
    • Ethereum
  • Economy
  • Energy
    • Electric
    • Oil & Gas
    • Renewables
  • Financial Services
    • Asset Management
    • Banks
    • Brokerages
    • Credit Services
    • Insurance
  • Healthcare
    • Biotechnology
    • Medical Devices
    • Pharmaceuticals
  • Industrials
    • Aerospace & Defense
    • Construction
    • Industrial Machinery
  • Materials
    • Building Materials
    • Chemicals
    • Gold
    • Mining
    • Silver
    • Steel
  • Q&A's
  • Real Estate
  • Technology
    • Artificial Intelligence
    • Computer Hardware
    • Consumer Electronics
    • Cybersecurity
    • IT Services
    • Semiconductors
    • Software
  • Utilities

Latest News

Anthropic Leveraged ETFs: What GraniteShares’ AIL and ANS Offer Traders

November 20, 2026

KULR Technology Secures $14.8 Million Purchase Order for Advanced Energy Storage Systems

November 18, 2026
chemistry-2

SELLAS Life Sciences Stock Soars 170% Following Positive Phase 3 Leukemia Vaccine Results

November 17, 2026
  • About
  • Privacy Policy
  • Contact

© 2024 All Rights Reserved: STOXPO.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Read More

In case of sale of your personal information, you may opt out by using the link Do Not Sell My Personal Information

Accept Cookie Settings
Cookies are small text files that can be used by websites to make a user's experience more efficient. The law states that we can store cookies on your device if they are strictly necessary for the operation of this site. For all other types of cookies we need your permission. This site uses different types of cookies. Some cookies are placed by third party services that appear on our pages.
  • Always Active
    Necessary
    Necessary cookies help make a website usable by enabling basic functions like page navigation and access to secure areas of the website. The website cannot function properly without these cookies.
  • Marketing
    Marketing cookies are used to track visitors across websites. The intention is to display ads that are relevant and engaging for the individual user and thereby more valuable for publishers and third party advertisers.
  • Analytics
    Analytics cookies help website owners to understand how visitors interact with websites by collecting and reporting information anonymously.
  • Preferences
    Preference cookies enable a website to remember information that changes the way the website behaves or looks, like your preferred language or the region that you are in.
  • Unclassified
    Unclassified cookies are cookies that we are in the process of classifying, together with the providers of individual cookies.
Cookie Settings

Do you really wish to opt-out?

No Result
View All Result
  • Latest News
  • Healthcare
    • Biotechnology
    • Pharmaceuticals
  • Technology
    • Software
    • Semiconductors
  • Crypto
    • Bitcoin
    • Ethereum
    • Altcoins
  • Companies
    • Micro-Cap
    • Small-Cap
    • Mid-Cap
    • Large-Cap
    • Mega-Cap
  • Q&A’s
  • Contributions

© 2024 All Rights Reserved: STOXPO.